Hot Stocks To Invest In 2014

Far too often, investors and advisors alike are guilty of falling prey to the allure of high returns. The rationale being, investing is all about clocking the highest return, hence any avenue that can deliver on this front gets the thumbs up. Don�� get us wrong. We are not suggesting that returns aren�� important or that there is necessarily something wrong with an avenue simply because it can deliver a better showing on the returns front vis-�-vis other avenues. However, selecting an investment avenue based solely on its performance is a flawed approach.

In the first place, such an approach erroneously assumes that the investment avenue (say a mutual fund for instance) is an end, rather than a means to achieve an end. While investing, the end should be a tangible goal like providing for one�� retirement , buying a car or simply wealth accumulation, expressed in monetary terms. And once the target sum has been established, appropriate avenues to achieve that end should be chosen. Conversely, if the investment process begins with the selection of the investment avenue, the investor ends up investing in an aimless manner and may never achieve his goals.

Best Value Stocks To Own Right Now: First Citizens BancShares Inc.(FCNCA)

First Citizens BancShares, Inc. operates as the holding company for First-Citizens Bank & Trust Company that provides various banking products and services to retail and commercial customers in the United States. It offers transaction and savings deposit accounts, commercial and consumer loans, deposit and treasury services and products, cardholder and merchant services, wealth management services, and other commercial banking services. The company also operates as a broker-dealer in securities that provides investment services, including the sale of annuities and third party mutual funds, as well as title insurance agency services. In addition, it owns and leases real estate properties. The company provides its services through branch, telephone and online banking, and automated teller machine network. It operates branches in 17 states and the District of Columbia. The company was founded in 1893 and headquartered in Raleigh, North Carolina.

Advisors' Opinion:

• [By Tim Melvin]

  First Citizens Bank and Trust (FCNCA) is another bank that has seen its returns slipping in the past year. The return on assets and return on equity have both dropping for three consecutive quarters. The tangible equity-to-assets ratio is improving, and now stands at 9.46 but is still below the national averages.

Hot Stocks To Invest In 2014: Martin Midstream Partners L.P.(MMLP)

Martin Midstream Partners L.P. collects, transports, stores, and markets petroleum products and by-products in the United States Gulf Coast region. The company?s Terminalling and Storage segment owns or operates 27 marine shore based terminal facilities and 12 specialty terminal facilities that provide storage, processing, and handling services for producers and suppliers of petroleum products and by-products, lubricants, and other liquids, including the refining of various grades and quantities of naphthenic lubricants and related products. This segment also offers land rental services to oil and gas companies, and storage and handling services for lubricants and fuel oil. The Natural Gas Services segment is involved in the gathering and processing of natural gas, and distribution of natural gas liquids (NGLs). This segment owns 1 NGL pipeline; and 3 NGL supply and storage facilities, as well as has ownership interests in approximately 719 miles of gathering and transmis sion pipelines located in the natural gas producing regions of east Texas, Northwest Louisiana, the Texas Gulf Coast and offshore Texas and federal waters in the Gulf of Mexico. The Sulfur Services segment processes and distributes sulfur produced by oil refineries that is primarily used in the production of fertilizers and industrial chemicals. This segment own and operates 6 sulfur-based fertilizer production plants, and 1 emulsified sulfur blending plant that manufacture sulfur-based fertilizer products for wholesale distributors and industrial users; 1 sulfuric acid production plant that processes molten sulfur into sulfuric acid; and 1 ammonium sulfate production plant that processes sulfuric acid into ammonium sulfate. The Marine Transportation segment utilizes a fleet of 41 inland marine tank barges, 20 inland push boats, and 4 offshore tug barge units that transport petroleum products and by-products. The company was founded in 2002 and is based in Kilgore, Texas.

Advisors' Opinion:

• [By Robert Rapier]

  The index includes everything from behemoths like Enterprise Product Partners (NYSE: EPD) and Kinder Morgan Energy Partners (NYSE: KMP) down to a pair with market capitalizations under $1 billion in Martin Midstream Partners (NASDAQ: MMLP) and Navios Maritime Partners (NYSE: NMM). The total market cap of the index is $328 billion, and its one-, three- and five-year total returns are 20 percent, 48 percent and 194 percent. The index yield is 6 percent.

• [By Jonas Elmerraji]

  Today, we're starting small with Martin Midstream Partners (MMLP), a $1.2 billion firm that transports and stores natural gas and sulfur. Shares of MMLP have had a stellar year in 2013, rallying more than 47% since the calendar flipped over to January -- and this stock's technicals point to even higher ground in the second half.

  That's because MMLP is currently forming an ascending triangle pattern, a technical setup that's formed by horizontal resistance above shares at $46 and uptrending support to the downside. Basically, as MMLP bounces in between those two technical price levels, it's getting squeezed closer and closer to a breakout above that $46 resistance level. When that breakout happens, we've got a buy signal for shares.

  Confirmation is going to be important to watch in MMLP. This stock has popped above $46 intraday in the past, only to fall back down to close within the pattern. Waiting for a close above $46 followed by a consecutive open above it greatly reduces the possibility of a bull trap in this stock.

• [By Aimee Duffy]

  The role of the barge can't be underestimated. Barge receipts increased more than two percentage points year over year, and this is a great place for investors to look for opportunity. Companies with maritime resources benefit from this trend, as well as growth in exports. Three such companies that are worth a look are:

  Kirby Corporation (NYSE: KEX  ) , which operates 30% of the coastal tank barges in the U.S.� Oiltanking Partners (NYSE: OILT  ) , which has storage capacity of 12.1 million barrels and six deepwater docks on the Houston Ship Channel Martin Midstream Partners (NASDAQ: MMLP  ) , which operates a large fleet of inland barges and controls 31 marine terminals�

  These companies won't be the only winners, but they are a good place to start your research.

Hot Stocks To Invest In 2014: Cytori Therapeutics Inc(CYTX)

Cytori Therapeutics, Inc. engages in the development, manufacture, and sale of medical products and devices to enable the practice of regenerative medicine. Regenerative medicines focus on repairing or restoring lost or damaged tissue and cell function. Its principal products include the Celution family of products, which processes patients' adipose-derived stem and regenerative cells (ADRCs) at the point of care. The Celution family of products consists of a central device, a related single-use consumable used for each patient procedure, proprietary enzyme reagents, and related instrumentation. Its core product, the Celution System, provides physicians with clinical grade stem and regenerative cells for use in the cosmetic and reconstructive surgery market. The company also provides PureGraft, a consumable product that provides grafts for use in aesthetic body contouring procedures. In addition, it sells the StemSource family of products worldwide, including in the United States, for research, as well as for the cryopreservation and storage of ADRCs. It offers the StemSource System as a standalone product, or as a part of a comprehensive suite of systems, equipment, and protocols collectively referred to as a StemSource Cell Bank. Further, the company develops Celution System, which has completed two clinical trials for applications in cardiovascular disease, wound healing, gastrointestinal disorders, stress urinary incontinence, liver and renal disease, spinal disc degeneration, and pelvic health conditions. It has strategic development and manufacturing joint venture agreement, and other related agreements with Olympus Corporation. The company was formerly known as MacroPore Biosurgery, Inc. Cytori Therapeutics, Inc. was founded in 1996 and is headquartered in San Diego, California.

Advisors' Opinion:

• [By James E. Brumley]

  If you're reading this, then odds are you already know that Cytori Therapeutics Inc. (NASDAQ:CYTX) is up a whopping 8% today. In some ways that's encouraging, as it proves there's a lot of trade-worthy momentum to be tapped. In other ways, however, it's bad, because CYTX is overbought and ripe for a pullback. No matter how you're seeing Cytori Therapeutics in the short run, though, when you take a step back and look at the longer-term picture, there's a lot to like.

• [By Tom Rojas var popups = dojo.query(".socialByline .popC"); popups.forEach(func]

  Cytori Therapeutics Inc.(CYTX) on Tuesday said it is putting a clinical hold on enrollment in two chronic-heart-failure clinical trials, citing safety concerns. Shares sank 32.9% to $1.41 premarket.

Hot Stocks To Invest In 2014: Rexahn Pharmaceuticals Inc (RNN)

Rexahn Pharmaceuticals, Inc. (Rexahn) is a development-stage biopharmaceutical company. The Company focuses on the development of cures for cancer to patients worldwide. The Company�� pipeline features one drug candidate in Phase II clinical trials. The Company also has several other drug candidates in pre-clinical development. In addition, the Company has two renal cell carcinoma (CNS) candidates, Serdaxin, CNS Disorders drug for depression and neurodegenerative diseases and Zoraxel, which is a erectile dysfunction (ED) and sexual dysfunction drug that are in clinical stages and the Company is are exploring options for further development . The Company�� drug candidate, Archexin is an anticancer Akt inhibitor.

Archexin

Archexin is potent inhibitor of the Akt protein kinase (Akt) in cancer cells. Archexin has FDA orphan drug designations for five cancers (RCC, glioblastoma, and cancers of the ovary, stomach and pancreas). Multiple indications for other solid tumors can also be pursued. Archexin inhibit both activated and inactivated forms of Akt, and to reverse the drug resistance observed with the protein kinase inhibitors. Archexin is an antisense oligonucleotide (ASO) compound that is complementary to Akt mRNA, and selective for inhibiting mRNA expression and production of Akt protein. As of December 31, 2011, Archexin was in Phase II clinical trials for the treatment of pancreatic cancer with enrollment completed in September, 2011.

Serdaxin

Serdaxin is an extended release formulation of clavulanic acid, which is an ingredient present in antibiotics approved by the FDA. The Company had been developing Serdaxin for the treatment of depression and neurodegenerative disorders. From January to September, 2011, the Company conducted a randomized, double-blind, placebo-controlled study compared two doses of Serdaxin, 0.5 milligram and 5 milligram, to placebo over an eight-week treatment period for major depressive disorder (MDD) patients. As of Dec! ember 31, 2011, the Company had not made a determination of Serdaxin�� future paths or resource allocations to further develop Serdaxin to treat MDD.

Zoraxel

Zoraxel is an orally administered, on-demand tablet to treat sexual dysfunction. Zoraxel is a dual enhancer of neurotransmitters in the brain that play a key role in sexual activity phases of motivation and arousal, erection and release, and may be the ED drug to affect all three of these phases of sexual activity. As of December 31, 2011, the Company was evaluating how to proceed with the Phase IIb study of Zoraxel.

The Company�� Pre-clinical Pipeline Drug Candidates includes RX-1792, which is a small molecule anticancer EGFR inhibitor; RX-5902, which is a small molecule anticancer ribonucleic acid (RNA) helicase regulator; RX-3117, which is a Small molecule anticancer deoxyribonucleic acid (DNA) synthesis Inhibitor; RX-8243, which is a small molecule anticancer aurora kinase inhibitor; RX-0201-Nano, which is a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, which is an nanoliposomal anticancer HIF-1 alpha inhibitor and RX-21101, which is a nano-polymer Anticancer.

Advisors' Opinion:

• [By John Udovich]

  So far this year, Rexahn Pharmaceuticals, Inc (NYSEMKT: RNN), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and Arrowhead Research Corp (NASDAQ: ARWR) are up 186.3%, 157.2% and 142.5%, respectively, since the start of the year���making them the best performing small cap biotech stocks for 2014. But given their lackluster performance over the past few years, what is the secret behind their phenomenal 2014 rise and will they keep rising? For starters, none of these small caps have really produced anything in the way of blockbuster news:

• [By James E. Brumley]

  If you were lucky enough to step into Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) when your truly suggested it was a budding buy back on December 23rd, then congratulations - you're now up a little more than 60% (assuming you bought into RNN after the break above a key resistance line on the 27th). Now get out. Instead, use your profits from the Rexahn to take on a stake in GTx, Inc. (NASDAQ:GTXI). No, GTXI may not look like much at first, but when you take a step back and look at a chart of GTx, Inc. through a longer-term lens, the upside potential becomes clear.

Hot Stocks To Invest In 2014: Celldex Therapeutics Inc(CLDX)

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. The company markets Rotarix to treat rotavirus infection. Its lead drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine in Phase III clinical trial to target the tumor-specific molecule, epidermal growth factor receptor variant III, as well as in Phase II clinical trial for the indication of recurrent glioblastoma. The company?s other lead drug candidates comprise CDX-011, an antibody-drug conjugate in Phase IIb clinical trial for metastatic breast cancer and melanoma indication; and CDX-1127, a human monoclonal antibody in Phase I clinical trial for the treatment of lymphoma/leukemia and solid tumors. Its additional clinical and preclinical programs consist of CDX-1401, an Antigen Presenting Cells Targeting Technology program in Phase I/II clinical trial to tr eat multiple solid tumors; and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor in Phase I clinical for treating cancer, autoimmune disease, and transplant. The company?s preclinical products include CDX-1135, a molecule for treating renal disease; and CDX-014, a human monoclonal antibody-drug conjugate for the treatment of ovarian and renal cancer. It has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; Duke University Brain Tumor Cancer Center; Ludwig Institute for Cancer Research; Alteris Therapeutics, Inc.; Thomas Jefferson University; 3M Company; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. Celldex Therapeutics, Inc. was founded in 1983 and is headquartered in Needham, Massachusetts.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Celldex Therapeutics (NASDAQ: CLDX) shares tumbled 2.79 percent to $27.52 after the company reported positive Phase 2 rindopepimut data in patients with recurrent glioblastoma.

Hot Stocks To Invest In 2014: Spirit Airlines Inc.(SAVE)

Spirit Airlines, Inc. provides passenger airline services. It provides travel opportunities principally to and from south Florida, the northeast United States, the Caribbean, and Latin America. The company also offers optional travel-related products or services. As of December 31, 2011, it had a fleet of 37 Airbus single-aisle aircrafts. The company was formerly known as Charter One and changed its name to Spirit Airlines, Inc. in 1992. Spirit Airlines, Inc. was founded in 1964 and is headquartered in Miramar, Florida.

Advisors' Opinion:

• [By Louis Navellier]

  Spirit Airlines (SAVE) is quickly becoming a favorite of budget travelers. Spirit is a no-frills airline that allows customer to take advantage of very low fares and then pay for any upgrades they may desire. Consumers seem to like it, as earnings are up more than 60% so far this year. The company is doing better than Wall Street was expecting and earnings estimates have been raised several times in the past month. Spirit Airlines just announced a bunch of seasonal routes for summer travel to places like Atlantic City and Myrtle Beach — that move should help drive profits all summer long. The stock is rated ����by Portfolio Grader and remains a ��trong Buy.��/p>